Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lessened its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 11.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 832,977 shares of the company's stock after selling 109,181 shares during the quarter. Candriam S.C.A. owned about 0.58% of Denali Therapeutics worth $16,976,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. FMR LLC increased its position in shares of Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the last quarter. Wellington Management Group LLP increased its holdings in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after purchasing an additional 903,683 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Denali Therapeutics by 44.8% during the 4th quarter. Fisher Asset Management LLC now owns 792,499 shares of the company's stock worth $16,151,000 after purchasing an additional 245,168 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after purchasing an additional 149,939 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. This represents a 10.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Price Performance

Denali Therapeutics stock traded down $1.74 during midday trading on Monday, reaching $14.95. The company's stock had a trading volume of 1,740,811 shares, compared to its average volume of 1,007,483. The stock's 50-day simple moving average is $20.80 and its 200-day simple moving average is $24.30. The stock has a market capitalization of $2.17 billion, a P/E ratio of -5.42 and a beta of 1.46. Denali Therapeutics Inc. has a 52-week low of $14.01 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DNLI. Stifel Nicolaus upgraded shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price for the company in a research note on Monday, December 16th. The Goldman Sachs Group cut their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. Finally, Morgan Stanley started coverage on Denali Therapeutics in a research note on Friday. They issued an "overweight" rating and a $33.00 price objective for the company. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $37.20.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.